Alzamend Neuro Inc (ALZN)

Aug 19, 2024, 9:41 AM EDT - 5 months ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 8:00 AM EDT - 5 months ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

May 7, 2024, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Apr 18, 2023, 8:00 AM EDT - 1 year ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 4, 2023, 6:30 AM EDT - 1 year ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Nov 28, 2022, 6:30 AM EST - 2 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 22, 2022, 8:05 AM EST - 2 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 21, 2022, 7:27 PM EST - 2 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 1, 2022, 6:30 AM EDT - 2 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Sep 22, 2022, 8:00 AM EDT - 2 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 17, 2021, 11:59 PM EST - 3 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 9:54 AM EST - 3 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Sep 30, 2021, 1:45 PM EDT - 3 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 11:54 AM EDT - 3 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 10:11 AM EDT - 3 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 3 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Aug 4, 2021, 6:30 AM EDT - 3 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Jul 30, 2021, 6:30 AM EDT - 3 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 28, 2021, 3:07 PM EDT - 3 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 23, 2021, 7:20 AM EDT - 3 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 6:30 AM EDT - 3 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 12, 2021, 6:00 AM EDT - 3 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 1, 2021, 11:23 AM EDT - 3 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 6:30 AM EDT - 3 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jun 17, 2021, 4:30 PM EDT - 3 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 16, 2021, 6:30 AM EDT - 3 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 3 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering